Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Net Margin (2018 - 2026)

Sunshine Biopharma filings provide 8 years of Net Margin readings, the most recent being 24.96% for Q4 2025.

  • On a quarterly basis, Net Margin fell 247.0% to 24.96% in Q4 2025 year-over-year; TTM through Dec 2025 was 16.46%, a 194.0% increase, with the full-year FY2025 number at 16.46%, down 174.0% from a year prior.
  • Net Margin hit 24.96% in Q4 2025 for Sunshine Biopharma, down from 3.14% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 783.75% in Q4 2021 to a low of 15440.43% in Q1 2021.
  • Median Net Margin over the past 5 years was 23.73% (2025), compared with a mean of 1569.91%.
  • The widest YoY moves for Net Margin: up 1443245bps in 2022, down -138054bps in 2022.
  • Sunshine Biopharma's Net Margin stood at 783.75% in 2021, then tumbled by -176bps to 596.78% in 2022, then skyrocketed by 97bps to 16.28% in 2023, then plummeted by -38bps to 22.49% in 2024, then decreased by -11bps to 24.96% in 2025.
  • The last three reported values for Net Margin were 24.96% (Q4 2025), 3.14% (Q3 2025), and 31.36% (Q2 2025) per Business Quant data.